| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jodie Ingles | Q63363978 |
| Christopher Semsarian | Q88316745 | ||
| Barry J Maron | Q113675641 | ||
| P2093 | author name string | Martin S Maron | |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypertrophic cardiomyopathy | Q1364270 |
| P304 | page(s) | 1249-54 | |
| P577 | publication date | 2015-03-31 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | New perspectives on the prevalence of hypertrophic cardiomyopathy | |
| P478 | volume | 65 |
| Q92973984 | A novel LAMP2 p.G93R mutation associated with mild Danon disease presenting with familial hypertrophic cardiomyopathy |
| Q94948179 | A role for actin flexibility in thin filament-mediated contractile regulation and myopathy |
| Q39384466 | ALPK3 gene mutation in a patient with congenital cardiomyopathy and dysmorphic features. |
| Q38377164 | AMSSM Position Statement on Cardiovascular Preparticipation Screening in Athletes: current evidence, knowledge gaps, recommendations and future directions. |
| Q92885378 | Access and Outcomes Among Hypertrophic Cardiomyopathy Patients in a Large Integrated Health System |
| Q47210536 | Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel |
| Q58565612 | Added value of cardiac deformation imaging in differential diagnosis of left ventricular hypertrophy |
| Q64232849 | Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy |
| Q38736582 | Attitudes, knowledge and consequences of uncertain genetic findings in hypertrophic cardiomyopathy. |
| Q92628607 | Bioinformatics analysis of the regulatory lncRNA‑miRNA‑mRNA network and drug prediction in patients with hypertrophic cardiomyopathy |
| Q30838224 | Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy |
| Q64120681 | Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them? |
| Q50086129 | CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase. |
| Q88613563 | CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy |
| Q49989673 | Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques, Findings, and Clinical Relevance |
| Q42373663 | Cardiomyocyte-Specific Telomere Shortening is a Distinct Signature of Heart Failure in Humans. |
| Q57818505 | Cardiovascular disease models: A game changing paradigm in drug discovery and screening |
| Q38769934 | Changes in the dynamics of the cardiac troponin C molecule explain the effects of Ca2+-sensitizing mutations |
| Q55028925 | Classifying Cardiac Actin Mutations Associated With Hypertrophic Cardiomyopathy. |
| Q48177445 | Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals |
| Q58565625 | Clinical presentations of hypertrophic cardiomyopathy and implications for therapy |
| Q64997486 | Clinicopathological and Genetic Profiles of Cases with Myocytes Disarray-Investigation for Establishing the Autopsy Diagnostic Criteria for Hypertrophic Cardiomyopathy. |
| Q36984660 | Comprehensive Versus Targeted Genetic Testing in Children with Hypertrophic Cardiomyopathy. |
| Q42119619 | Contractility parameters of human β-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. |
| Q90286423 | Converter domain mutations in myosin alter structural kinetics and motor function |
| Q58106412 | Coronary arterial vasculature in the pathophysiology of hypertrophic cardiomyopathy |
| Q61761490 | Coverage and diagnostic yield of Whole Exome Sequencing for the Evaluation of Cases with Dilated and Hypertrophic Cardiomyopathy |
| Q90347243 | Current state of the roles of alcohol septal ablation and surgical myectomy in the treatment of hypertrophic obstructive cardiomyopathy |
| Q45999934 | Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results. |
| Q88185215 | Development of apical hypertrophic cardiomyopathy with age in a transgenic mouse model carrying the cardiac actin E99K mutation |
| Q36999686 | Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy. |
| Q48562784 | Early marker of regional left ventricular deformation in patients with hypertrophic cardiomyopathy evaluated by MRI tissue tracking: The effects of myocardial hypertrophy and fibrosis |
| Q38379334 | Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial |
| Q26770578 | Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosin |
| Q99207766 | Epidemiology of the inherited cardiomyopathies |
| Q91410532 | Establishing a new human hypertrophic cardiomyopathy-specific model using human embryonic stem cells |
| Q47132748 | EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM)-rationale and design: a prospective observational study on incidence of arrhythmias in Sweden. |
| Q64230892 | Evaluating a custom-designed aid to improve communication of genetic results in families with hypertrophic cardiomyopathy: study protocol for a randomised controlled trial |
| Q64253974 | Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes |
| Q40156224 | Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes |
| Q100385884 | Examining the impact of inducible ischemia on myocardial fibrosis and exercise capacity in hypertrophic cardiomyopathy |
| Q92991260 | Exploring the Continuum of Hypertrophic Cardiomyopathy-From DNA to Clinical Expression |
| Q64284619 | Extra energy for hearts with a genetic defect: ENERGY trial |
| Q50900139 | Familial hypertrophic cardiomyopathy caused by a de novo Gly716Arg mutation of the β-myosin heavy chain. |
| Q90421467 | Family Relationships Associated With Communication and Testing for Inherited Cardiac Conditions |
| Q47553665 | Finding the candidate sequence variants for diagnosis of hypertrophic cardiomyopathy in East Slovak patients. |
| Q36054601 | General Practitioners' knowledge and use of genetic counselling in managing patients with genetic cardiac disease in non-specialised settings |
| Q49569539 | Genetic association between 1425G/A SNP in PRKCH and hypertrophic cardiomyopathy in a Chinese population |
| Q30238784 | Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association |
| Q33580919 | Hypertrophic Cardiomyopathy Cardiac Troponin C Mutations Differentially Affect Slow Skeletal and Cardiac Muscle Regulation. |
| Q30278822 | Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy |
| Q52371503 | Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits. |
| Q42515078 | Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy |
| Q38863215 | Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline |
| Q64263189 | Hypertrophic Obstructive Cardiomyopathy |
| Q39440818 | Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light |
| Q45339581 | Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage |
| Q33167969 | Hypertrophic obstructive cardiomyopathy |
| Q37472878 | III SBC Guidelines on the Analysis and Issuance of Electrocardiographic Reports - Executive Summary |
| Q41698112 | Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of outcomes and complications |
| Q33795234 | Increased Postnatal Cardiac Hyperplasia Precedes Cardiomyocyte Hypertrophy in a Model of Hypertrophic Cardiomyopathy |
| Q52585310 | International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study. |
| Q96343427 | Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics |
| Q33644541 | LAMP2 shines a light on cardiomyopathy in an athlete |
| Q88574795 | LGE-CMR-derived texture features reflect poor prognosis in hypertrophic cardiomyopathy patients with systolic dysfunction: preliminary results |
| Q99238015 | Large Animal Models in Regenerative Medicine and Tissue Engineering: To Do or Not to Do |
| Q52347412 | Left ventricular hypertrophy diagnosed after a stroke: a case report. |
| Q42320941 | Life-long tailoring of management for patients with hypertrophic cardiomyopathy : Awareness and decision-making in changing scenarios. |
| Q33655255 | Living with hypertrophic cardiomyopathy and an implantable defibrillator |
| Q36907007 | Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients |
| Q41013371 | MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. |
| Q36984520 | Maturation of Lesions Induced by Myocardial Cavitation-Enabled Therapy |
| Q94544776 | Mechanisms of Arrhythmogenicity in Hypertrophic Cardiomyopathy: Insight From Non-invasive Electrocardiographic Imaging |
| Q92012621 | Metabolic Alterations in Inherited Cardiomyopathies |
| Q61651710 | Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology |
| Q114871157 | Mitochondrial–cell cycle cross-talk drives endoreplication in heart disease |
| Q34549974 | Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels. |
| Q91779289 | Molecular autopsy and family screening in a young case of sudden cardiac death reveals an unusually severe case of FHL1 related hypertrophic cardiomyopathy |
| Q28069286 | Molecular autopsy in victims of inherited arrhythmias |
| Q47145030 | Multiple ultrasound cavitation-enabled treatments for myocardial reduction |
| Q101224925 | Mutation location of HCM-causing troponin T mutations defines the degree of myofilament dysfunction in human cardiomyocytes |
| Q92787117 | MyBP-C: one protein to govern them all |
| Q52808499 | Myocardial Effective Transverse Relaxation Time T 2* is Elevated in Hypertrophic Cardiomyopathy: A 7.0 T Magnetic Resonance Imaging Study. |
| Q64986591 | Myocardial adaptation after surgical therapy differs for aortic valve stenosis and hypertrophic obstructive cardiomyopathy. |
| Q51033685 | Myosin Rod Hypophosphorylation and CB Kinetics in Papillary Muscles from a TnC-A8V KI Mouse Model. |
| Q35910178 | Myosin light chain phosphorylation to the rescue |
| Q33647442 | Myosin-binding Protein C Compound Heterozygous Variant Effect on the Phenotypic Expression of Hypertrophic Cardiomyopathy |
| Q57803950 | N-terminal extension in cardiac myosin-binding protein C regulates myofilament binding |
| Q92240141 | Novel Therapies for Prevention and Early Treatment of Cardiomyopathies |
| Q41627235 | Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models. |
| Q47340487 | Pathogenesis of depression- and anxiety-like behavior in an animal model of hypertrophic cardiomyopathy |
| Q93174381 | Pathogenic troponin T mutants with opposing effects on myofilament Ca2+ sensitivity attenuate cardiomyopathy phenotypes in mice |
| Q51557395 | Patient-specific CT-based 3D passive FSI model for left ventricle in hypertrophic obstructive cardiomyopathy. |
| Q47248403 | Percutaneous trans-apex intra-septal radiofrequency ablation of hypertrophic cardiomyopathy. |
| Q38816364 | Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. |
| Q91657436 | Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue |
| Q37133765 | Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers |
| Q92792367 | Potential digenic inheritance of familial hypertrophic cardiomyopathy identified by whole-exome sequencing |
| Q58757143 | Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE |
| Q40488679 | Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. |
| Q37455349 | Presymptomatic diagnosis of Fabry's disease: a case report |
| Q37316321 | Prevalence and Phenotypic Expression of Mutations in the MYH7, MYBPC3 and TNNT2 Genes in Families with Hypertrophic Cardiomyopathy in the South of Brazil: A Cross-Sectional Study |
| Q52803438 | Prevalence of clinically apparent hypertrophic cardiomyopathy in Germany-An analysis of over 5 million patients. |
| Q90124400 | Prevention of sudden cardiac death in hypertrophic cardiomyopathy: Risk assessment using left atrial diameter predicted from left atrial volume |
| Q64970128 | Prognostic significance of anterior mitral valve leaflet length in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes. |
| Q92027205 | Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy |
| Q57187604 | Psychosocial Impact of a Positive Gene Result for Asymptomatic Relatives at Risk of Hypertrophic Cardiomyopathy |
| Q92393028 | Quantification of left atrial function in patients with non-obstructive hypertrophic cardiomyopathy by cardiovascular magnetic resonance feature tracking imaging: a feasibility and reproducibility study |
| Q89804842 | RNA Splicing Defects in Hypertrophic Cardiomyopathy: Implications for Diagnosis and Therapy |
| Q37424109 | Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. |
| Q51732920 | Relationship between left ventricular diastolic dyssynchrony and systolic dyssynchrony in hypertrophic cardiomyopathy by single-cardiac real-time three-dimensional ultrasonography. |
| Q50926615 | Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model. |
| Q64090561 | Revealing the mechanism of how cardiac myosin-binding protein C N-terminal fragments sensitize thin filaments for myosin binding |
| Q90640499 | Risk of end-stage renal disease in patients with hypertrophic cardiomyopathy: A nationwide population-based cohort study |
| Q92092459 | Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap? |
| Q45069359 | Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy |
| Q40492999 | Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal |
| Q47116170 | Routinely collected health data to study inherited heart disease: a systematic review (2000-2016). |
| Q90016976 | Screening of MYH7 gene mutation sites in hypertrophic cardiomyopathy and its significance |
| Q40042653 | Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model. |
| Q49948254 | Septal myectomy for hypertrophic cardiomyopathy: important surgical knowledge and technical tips in the era of increasing alcohol septal ablation |
| Q92335260 | Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy |
| Q94539021 | Sex-specific cardiac remodeling in early and advanced stages of hypertrophic cardiomyopathy |
| Q90442261 | Sexual dimorphism in cardiac transcriptome associated with a troponin C murine model of hypertrophic cardiomyopathy |
| Q40857990 | Significance of apical cavity obliteration in apical hypertrophic cardiomyopathy |
| Q47378513 | Structural destabilization of tropomyosin induced by the cardiomyopathy-linked mutation R21H. |
| Q47216701 | Sudden Cardiac Arrest during Participation in Competitive Sports |
| Q59796614 | Sudden Death in Young Brazilian Athletes: Isn't It Time We Created a Genuinely National Register? |
| Q91958870 | Survival Differences in Women and Men After Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy |
| Q41696597 | Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis |
| Q100530306 | Targeting the population for gene therapy with MYBPC3 |
| Q53108123 | The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care. |
| Q49926548 | The HCM-linked W792R mutation in cardiac myosin binding protein-C reduces C6 FnIII domain stability |
| Q42491603 | The L-type Ca(2+) channel facilitates abnormal metabolic activity in the cTnI-G203S mouse model of hypertrophic cardiomyopathy. |
| Q91878266 | The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin |
| Q92069879 | The mechanisms, diagnosis and management of mitral regurgitation in mitral valve prolapse and hypertrophic cardiomyopathy |
| Q92175201 | The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy |
| Q88453324 | Thick Filament Protein Network, Functions, and Disease Association |
| Q64232857 | Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations |
| Q47317140 | Three-dimensional cardiovascular imaging-genetics: a mass univariate framework |
| Q58556681 | Transcriptome Analysis of Cardiac Hypertrophic Growth in -Null Mice Suggests Early Responders in Hypertrophic Remodeling |
| Q88433042 | Ultrasonic Cavitation-Enabled Treatment for Therapy of Hypertrophic Cardiomyopathy: Proof of Principle |
| Q38743378 | Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease Models |
| Q87141452 | Unusual combination: Ebstein's anomaly and hypertrophic obstructive cardiomyopathy |
| Q93137568 | Update on cardiomyopathies and sudden cardiac death |
| Q30245043 | Update on hypertrophic cardiomyopathy and a guide to the guidelines. |
| Q92568756 | Utility of genetic testing in athletes |
| Q64975098 | Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy. |
| Q42378622 | Which way to grow? Force over time may be the heart's Dao de jing |
| Q91296455 | Whole MYBPC3 NGS sequencing as a molecular strategy to improve the efficiency of molecular diagnosis of patients with hypertrophic cardiomyopathy |
Search more.